|
1
|
Wang ZY and Chen Z: Acute promyelocytic
leukemia: From highly fatal to highly curable. Blood.
111:2505–2515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Albano F, Zagaria A, Anelli L, Coccaro N,
Tota G, Brunetti C, Minervini CF, Impera L, Minervini A, Cellamare
A, et al: Absolute quantification of the pretreatment PML-RARA
transcript defines the relapse risk in acute promyelocytic
leukemia. Oncotarget. 6:13269–13277. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Powell BL: Arsenic trioxide in acute
promyelocytic leukemia: Potion not poison. Expert Rev Anticancer
Ther. 11:1317–1319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang K, Li J, Meng W, Xing H and Yang Y:
Tanshinone IIA inhibits acute promyelocytic leukemia cell
proliferation and induces their apoptosis in vivo. Blood Cells Mol
Dis. 56:46–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li L, Song H, Zhong L, Yang R, Yang XQ,
Jiang KL and Liu BZ: Lithium chloride promotes apoptosis in human
leukemia NB4 cells by inhibiting glycogen synthase kinase-3 beta.
Int J Med Sci. 12:805–810. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iland HJ, Bradstock K, Supple SG, Catalano
A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A,
et al: All-trans-retinoic acid, idarubicin and IV arsenic trioxide
as initial therapy in acute promyelocytic leukemia (APML4). Blood.
120:1570–1580. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ghavamzadeh A, Alimoghaddam K, Rostami S,
Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B and Jalili M:
Phase II study of single-agent arsenic trioxide for the front-line
therapy of acute promyelocytic leukemia. J Clin Oncol.
29:2753–2757. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Papathanasiou K, Papageorgiou C, Panidis D
and Mantalenakis S: Our experience in laparoscopic diagnosis and
management in women with chronic pelvic pain. Clin Exp Obstet
Gynecol. 26:190–192. 1999.PubMed/NCBI
|
|
9
|
Chen X, Yang L, Oppenheim JJ and Howard
MZ: Cellular pharmacology studies of shikonin derivatives.
Phytother Res. 16:199–209. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gaddipati JP, Mani H, Shefali, Raj K,
Mathad VT, Bhaduri AP and Maheshwari RK: Inhibition of growth and
regulation of IGFs and VEGF in human prostate cancer cell lines by
shikonin analogue 93/637 (SA). Anticancer Res. 20:2547–2552.
2000.PubMed/NCBI
|
|
11
|
Min R, Tong J, Wenjun Y, Wenhu D, Xiaojian
Z, Jiacai H, Jian Z, Wantao C and Chenping Z: Growth inhibition and
induction of apoptosis in human oral squamous cell carcinoma
Tca-8113 cell lines by shikonin was partly through the inactivation
of NF-kappaB Pathway. Phytother Res. 22:407–415. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mao X, Yu CR, Li WH and Li WX: Induction
of apoptosis by shikonin through a ROS/JNK mediated process in
Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell
Res. 18:879–888. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gong K and Li W: Shikonin, a Chinese
plant-derived naphthoquinone, induces apoptosis in hepatocellular
carcinoma cells through reactive oxygen species: A potential new
treatment for hepatocellular carcinoma. Free Radic Biol Med.
51:2259–2271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang Q, Ji M, Guan H, Shi B and Hou P:
Shikonin inhibits thyroid cancer cell growth and invasiveness
through targeting major signaling pathways. J Clin Endocrinol
Metab. 98:E1909–E1917. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Q, Assimopoulou AN, Klauck SM,
Damianakos H, Chinou I, Kretschmer N, Rios JL, Papageorgiou VP,
Bauer R and Efferth T: Inhibition of c-MYC with involvement of
ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and
its derivatives in killing leukemia cells. Oncotarget.
6:38934–38951. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang W and Liu HT: MAPK signal pathways
in the regulation of cell proliferation in mammalian cells. Cell
Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cobb MH: MAP kinase pathways. Prog Biophys
Mol Biol. 71:479–500. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dent P and Grant S: Pharmacologic
interruption of the mitogen-activated extracellularregulated
kinase/mitogen-activated protein kinase signal transduction
pathway: Potential role in promoting. Clin Cancer Res. 7:775–783.
2001.PubMed/NCBI
|
|
19
|
Fan M and Chambers TC: Role of
mitogen-activated protein kinases in the response of tumor cells to
chemotherapy. Drug Resist Updat. 4:253–267. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dent P and Grant S: Pharmacologic
interruption of the mitogen-activated extracellular-regulated
kinase/mitogen-activated protein kinase signal transduction
pathway: Potential role in promoting cytotoxic drug action. Clin
Cancer Res. 7:775–783. 2001.PubMed/NCBI
|
|
21
|
Hsu PC, Huang YT, Tsai ML, Wang YJ, Lin JK
and Pan MH: Induction of apoptosis by shikonin through coordinative
modulation of the Bcl-2 family, p27, and p53, release of cytochrome
c, and sequential activation of caspases in human colorectal
carcinoma cells. J Agric Food Chem. 52:6330–6337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van Engeland M, Ramaekers FC, Schutte B
and Reutelingsperger CP: A novel assay to measure loss of plasma
membrane asymmetry during apoptosis of adherent cells in culture.
Cytometry. 24:131–139. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moon DO, Kim MO, Choi YH, Kim ND, Chang JH
and Kim GY: Bcl-2 overexpression attenuates SP600125-induced
apoptosis in human leukemia U937 cells. Cancer Lett. 264:316–325.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cross TG, Scheel-Toellner D, Henriquez NV,
Deacon E, Salmon M and Lord JM: Serine/threonine protein kinases
and apoptosis. Exp Cell Res. 256:34–41. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park HS, Hwang HJ, Kim GY, Cha HJ, Kim WJ,
Kim ND, Yoo YH and Choi YH: Induction of apoptosis by fucoidan in
human leukemia U937 cells through activation of p38 MAPK and
modulation of Bcl-2 family. Mar Drugs. 11:2347–2364. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pan XN, Chen JJ, Wang LX, Xiao RZ, Liu LL,
Fang ZG, Liu Q, Long ZJ and Lin DJ: Inhibition of c-Myc overcomes
cytotoxic drug resistance in acute myeloid leukemia cells by
promoting differentiation. PLoS One. 9:e1053812014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu JJ, Meng LH, Shankavaram UT, Zhu CH,
Tong LJ, Chen G, Lin LP, Weinstein JN and Ding J:
Dihydroartemisinin accelerates c-MYC oncoprotein degradation and
induces apoptosis in c-MYC-overexpressing tumor cells. Biochem
Pharmacol. 80:22–30. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ganesan S: MYC, PARP1, and
chemoresistance: BIN there, done that? Sci Signal. 4:pe152011.
View Article : Google Scholar : PubMed/NCBI
|
